Iterum Therapeutics plc(ITRM)Earnings, Financials & Key Ratios
ITRM•NASDAQ
$0.03
$2M mkt cap·Price updated Apr 24, 2026
AboutIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Show more
- Revenue$0
- EBITDA-$18M+59.7%
- Net Income-$25M+35.4%
- EPS (Diluted)-1.26+57.4%
- ROIC-117.78%+28.1%
ITRM Key Insights
Iterum Therapeutics plc (ITRM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 0 (bottom 0%)
- ✗Shares diluted 52.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ITRM Price & Volume
Iterum Therapeutics plc (ITRM) stock price & volume — 10-year historical chart
Loading chart...
ITRM Growth Metrics
Iterum Therapeutics plc (ITRM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM11.76%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM62.5%
Return on Capital
10 Years-111.69%
5 Years-85.94%
3 Years-91.11%
Last Year-94.11%
ITRM Peer Comparison
Iterum Therapeutics plc (ITRM) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 SPRO | 142.47M | 2.53 | -1.99 | -53.77% | -122.56% | -165.46% | 0.09 | |
 VNDA | 439.76M | 7.44 | -1.99 | 8.72% | -102.02% | -49.24% | 0.04 | |
 CMPX | 329.72M | 1.85 | -4.40 | -100% | -43.61% | 0.05 | ||
 MTNB | 4.01M | 0.68 | -0.14 | -100% | -270.65% | 0.38 | ||
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 TARS | 2.76B | 64.76 | -40.73 | 146.71% | -9.02% | -14.19% | 0.27 |
Compare ITRM vs Peers
Iterum Therapeutics plc (ITRM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ITRM Income Statement
Iterum Therapeutics plc (ITRM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 508K | 869K | 37K | 0 | 0 | 0 | 0 | 0 | 390K |
| Revenue Growth % | - | - | 71.06% | -95.74% | -100% | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 161K | 2.1M | 1.8M | 1.75M | 254K | 1.06M |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 508K▲ 0% | 869K▲ 71.1% | 37K▼ 95.7% | -161K▼ 535.1% | -2.1M▼ 1206.8% | -1.8M▲ 14.4% | -1.75M▲ 2.8% | -254K▲ 85.5% | -668K▲ 0% |
| Gross Margin % | - | 100% | 100% | 100% | - | - | - | - | - | -171.28% |
| Gross Profit Growth % | - | - | 71.06% | -95.74% | -535.14% | -1206.83% | 14.45% | 2.78% | 85.49% | - |
| Operating Expenses | 13.36M | 29.96M | 77.43M | 102.06M | 31.96M | 22.43M | 28.58M | 45.72M | 18.44M | 19.62M |
| OpEx % of Revenue | - | 5898.23% | 8910.01% | 275832.43% | - | - | - | - | - | - |
| Selling, General & Admin | 3.26M | 4.46M | 8.78M | 11.28M | 11.05M | 13.82M | 12.77M | 7.48M | 7.98M | 15.57M |
| SG&A % of Revenue | - | 878.74% | 1010.47% | 30497.3% | - | - | - | - | - | - |
| Research & Development | 10.1M | 25.5M | 68.65M | 90.77M | 20.91M | 8.61M | 15.82M | 38.24M | 10.46M | 3.8M |
| R&D % of Revenue | - | 5019.49% | 7899.54% | 245335.14% | - | - | - | - | - | - |
| Other Operating Expenses | 8K | 0 | 401K | 196K | 0 | 0 | 0 | 0 | 0 | 254K |
| Operating Income | -13.36M▲ 0% | -29.45M▼ 120.5% | -76.56M▼ 159.9% | -102.02M▼ 33.3% | -32.13M▲ 68.5% | -24.54M▲ 23.6% | -30.38M▼ 23.8% | -47.47M▼ 56.2% | -18.7M▲ 60.6% | -20.29M▲ 0% |
| Operating Margin % | - | -5798.23% | -8810.01% | -275732.43% | - | - | - | - | - | -5202.82% |
| Operating Income Growth % | - | -120.49% | -159.92% | -33.26% | 68.51% | 23.62% | -23.83% | -56.23% | 60.61% | - |
| EBITDA | 0 | -29.39M | -76.42M | -101.87M | -31.96M | -22.43M | -28.58M | -45.72M | -18.41M | -18.98M |
| EBITDA Margin % | - | -5785.43% | -8794.36% | -275321.62% | - | - | - | - | - | -4865.38% |
| EBITDA Growth % | - | - | -160.03% | -33.3% | 68.62% | 29.82% | -27.41% | -59.95% | 59.73% | 27% |
| D&A (Non-Cash Add-back) | 13.36M | 65K | 136K | 152K | 161K | 2.1M | 1.8M | 1.75M | 284K | 1.32M |
| EBIT | -13.35M | -29.45M | -76.16M | -101.83M | -36.17M | -85.31M | -41.77M | -36.33M | -22.01M | -24.39M |
| Net Interest Income | 0 | 277K | -426K | -861K | -15.09M | -5.55M | -2.36M | 1.43M | 0 | -2.17M |
| Interest Income | 0 | 277K | 0 | 0 | 12.3K | 4.53K | 2.36K | 1.43M | 0 | 133K |
| Interest Expense | 0 | 0 | 426K | 861K | 15.1M | 5.55M | 2.36M | 0 | 0 | 2.3M |
| Other Income/Expense | 8K | 493K | -25K | -665K | -19.14M | -66.32M | -13.75M | 9.71M | -5.84M | -6.39M |
| Pretax Income | -13.35M▲ 0% | -28.96M▼ 116.9% | -76.58M▼ 164.4% | -102.69M▼ 34.1% | -51.26M▲ 50.1% | -90.86M▼ 77.2% | -44.13M▲ 51.4% | -37.76M▲ 14.4% | -24.53M▲ 35.0% | -26.68M▲ 0% |
| Pretax Margin % | - | -5701.18% | -8812.89% | -277529.73% | - | - | - | - | - | -6842.31% |
| Income Tax | 113K | 444K | 472K | 444K | 743K | 705K | 301K | 613K | 240K | 276K |
| Effective Tax Rate % | -0.85% | -1.53% | -0.62% | -0.43% | -1.45% | -0.78% | -0.68% | -1.62% | -0.98% | -1.03% |
| Net Income | -13.46M▲ 0% | -29.41M▼ 118.4% | -77.06M▼ 162.0% | -103.13M▼ 33.8% | -52.01M▲ 49.6% | -91.56M▼ 76.1% | -44.43M▲ 51.5% | -38.37M▲ 13.6% | -24.77M▲ 35.4% | -26.96M▲ 0% |
| Net Margin % | - | -5788.58% | -8867.2% | -278729.73% | - | - | - | - | - | -6913.08% |
| Net Income Growth % | - | -118.4% | -162.04% | -33.84% | 49.57% | -76.06% | 51.47% | 13.64% | 35.44% | 11.76% |
| Net Income (Continuing) | -13.46M | -29.41M | -77.06M | -103.13M | -52.01M | -91.56M | -44.43M | -38.37M | -24.77M | -26.96M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -26.59▲ 0% | -58.08▼ 118.4% | -98.32▼ 69.3% | -7.10▲ 92.8% | -32.49▼ 357.6% | -8.41▲ 74.1% | -3.63▲ 56.8% | -2.96▲ 18.5% | -1.26▲ 57.4% | -0.59▲ 0% |
| EPS Growth % | - | -118.43% | -69.28% | 92.78% | -357.61% | 74.12% | 56.84% | 18.46% | 57.43% | 62.5% |
| EPS (Basic) | -26.59 | -58.08 | -98.32 | -7.10 | -32.49 | -8.41 | -3.63 | -2.96 | -1.26 | - |
| Diluted Shares Outstanding | 13.96M | 549.15K | 631.57K | 1.05M | 24.01M | 10.89M | 12.24M | 12.96M | 19.7M | 45.8M |
| Basic Shares Outstanding | 13.96M | 549.15K | 631.57K | 1.05M | 24.01M | 10.89M | 12.24M | 12.96M | 19.7M | 45.8M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ITRM Balance Sheet
Iterum Therapeutics plc (ITRM) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 25.86M | 44.17M | 84.67M | 9.38M | 21.47M | 83.27M | 62.44M | 25.6M | 24.79M | 13.73M |
| Cash & Short-Term Investments | 24.81M | 39.22M | 84.67M | 4.83M | 14.57M | 81.34M | 60.8M | 23.93M | 24.13M | 11M |
| Cash Only | 24.81M | 8.48M | 44.55M | 4.83M | 14.57M | 27.45M | 21.09M | 6.07M | 24.13M | 11M |
| Short-Term Investments | 0 | 30.73M | 40M | 0 | 0 | 53.9M | 39.71M | 17.86M | 0 | 0 |
| Accounts Receivable | 245K | 509K | 721K | 1.11M | 865K | 1.21M | 513K | 233K | 66K | 546K |
| Days Sales Outstanding | - | 365.72 | 302.84 | 10.96K | - | - | - | - | - | 166.36 |
| Inventory | 0 | 0 | -7.87M | 0 | 0 | 0 | 0 | 0 | 0 | 1.15M |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | 226.83 |
| Other Current Assets | 0 | 180K | 959K | 1.14M | 5.24M | 37K | 35K | 0 | 65K | 0 |
| Total Non-Current Assets | 1.05M | 2.58M | 13.2M | 16.37M | 11.32M | 8.24M | 4.39M | 663K | 19.81M | 18.78M |
| Property, Plant & Equipment | 0 | 747K | 700K | 7.72M | 5.68M | 3.83M | 1.84M | 600K | 23K | 18K |
| Fixed Asset Turnover | - | 0.68x | 1.24x | 0.00x | - | - | - | - | - | 21.97x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 3.44M | 1.72M | 0 | 19.75M | 18.71M |
| Long-Term Investments | 0 | 0 | 959K | 60K | 248K | 64K | 34K | 0 | 0 | 63K |
| Other Non-Current Assets | 1.05M | 1.84M | 11.54M | 8.6M | 5.39M | 912K | 797K | 63K | 39K | 117K |
| Total Assets | 26.92M▲ 0% | 46.76M▲ 73.7% | 97.87M▲ 109.3% | 25.75M▼ 73.7% | 32.79M▲ 27.3% | 91.51M▲ 179.1% | 66.83M▼ 27.0% | 26.26M▼ 60.7% | 44.59M▲ 69.8% | 32.5M▲ 0% |
| Asset Turnover | - | 0.01x | 0.01x | 0.00x | - | - | - | - | - | 0.01x |
| Asset Growth % | - | 73.71% | 109.32% | -73.69% | 27.34% | 179.06% | -26.97% | -60.71% | 69.83% | 381.94% |
| Total Current Liabilities | 4.22M | 7.13M | 12.22M | 36.99M | 41.7M | 12.94M | 9.06M | 13.52M | 17.61M | 6.43M |
| Accounts Payable | 1.48M | 3.15M | 4.04M | 15.49M | 816K | 878K | 2.77M | 5M | 251K | 577K |
| Days Payables Outstanding | - | - | - | - | 1.85K | 152.31 | 562.51 | 1.04K | 360.69 | 209.58 |
| Short-Term Debt | 0 | 0 | 1.02M | 6.38M | 7.06M | 2.09M | 332K | 0 | 14.46M | 281K |
| Deferred Revenue (Current) | 0 | 0 | 113K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.95M | 2.92M | 5.24M | 13.71M | 32.75M | 8.98M | 3.99M | 761K | 240K | 4.67M |
| Current Ratio | 6.13x | 6.20x | 6.93x | 0.25x | 0.51x | 6.43x | 6.89x | 1.89x | 1.41x | 1.41x |
| Quick Ratio | 6.13x | 6.20x | 7.57x | 0.25x | 0.51x | 6.43x | 6.89x | 1.89x | 1.41x | 1.41x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 183.61 |
| Total Non-Current Liabilities | 30K | 137K | 26.25M | 15M | 41.65M | 28.33M | 29.77M | 19.14M | 31.07M | 33.45M |
| Long-Term Debt | 0 | 0 | 13.08M | 7.63M | 35.85M | 24.9M | 28.47M | 18.96M | 31.07M | 33.45M |
| Capital Lease Obligations | 0 | 0 | 0 | 6.75M | 5.17M | 3.44M | 1.3M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 30K | 137K | 951K | 630K | 630K | 0 | 0 | 188K | 0 | 0 |
| Total Liabilities | 4.25M | 7.26M | 26.25M | 51.99M | 83.35M | 41.27M | 38.83M | 32.66M | 48.68M | 39.88M |
| Total Debt | 0 | 0 | 13.08M | 20.75M | 48.08M | 30.43M | 30.1M | 18.96M | 45.53M | 33.73M |
| Net Debt | -24.81M | -8.48M | -31.47M | 15.92M | 33.52M | 2.98M | 9.01M | 12.88M | 21.41M | 22.73M |
| Debt / Equity | - | - | 0.18x | - | - | 0.61x | 1.08x | - | - | -4.57x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.78x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.20x |
| Interest Coverage | - | - | -179.72x | -118.49x | -2.13x | -4.42x | -12.87x | - | - | -10.61x |
| Total Equity | 22.67M▲ 0% | 39.49M▲ 74.2% | 71.62M▲ 81.3% | -26.24M▼ 136.6% | -50.56M▼ 92.7% | 50.23M▲ 199.4% | 28M▼ 44.3% | -6.4M▼ 122.9% | -4.08M▲ 36.3% | -7.38M▲ 0% |
| Equity Growth % | - | 74.23% | 81.35% | -136.63% | -92.69% | 199.36% | -44.26% | -122.87% | 36.26% | 194.97% |
| Book Value per Share | 1.62 | 71.92 | 113.40 | -24.99 | -2.11 | 4.61 | 2.29 | -0.49 | -0.21 | -0.16 |
| Total Shareholders' Equity | 22.67M | 39.49M | 71.62M | -26.24M | -50.56M | 50.23M | 28M | -6.4M | -4.08M | -7.38M |
| Common Stock | 4K | 4K | 144K | 149K | 494K | 1.83M | 126K | 135K | 315K | 490K |
| Retained Earnings | -25.33M | -54.74M | -131.79M | -234.92M | -286.93M | -378.49M | -422.93M | -461.3M | -486.07M | -506.45M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -65K | -201K | 0 | 0 | 0 | -350K | 1K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ITRM Cash Flow Statement
Iterum Therapeutics plc (ITRM) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -11.3M | -30.6M | -75.89M | -81.92M | -54.53M | -15.84M | -18.47M | -39.33M | -26.77M | -26.77M |
| Operating CF Margin % | - | -6024.41% | -8733.03% | -221410.81% | - | - | - | - | - | - |
| Operating CF Growth % | - | -170.88% | -147.97% | -7.95% | 33.44% | 70.95% | -16.61% | -112.91% | 31.93% | -20.52% |
| Net Income | -13.46M | -29.41M | -77.06M | -103.13M | -52.01M | -91.56M | -44.43M | -38.37M | -24.77M | -26.96M |
| Depreciation & Amortization | 0 | 65K | 136K | 152K | 161K | 2.1M | 1.8M | 1.75M | 284K | 1.32M |
| Stock-Based Compensation | 348K | 392K | 1.29M | 2.17M | 2.76M | 4.32M | 22.11M | 784K | 363K | 206K |
| Deferred Taxes | 0 | 44K | -701K | 0 | 1.41M | 61.6M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -830K | -95K | 2.04M | 984K | 17.71M | 8.14M | -258K | -6.26M | 10.09M | 8.42M |
| Working Capital Changes | 1.82M | -1.6M | -1.6M | 17.9M | -24.56M | -440K | 2.31M | 2.76M | -12.73M | -2.9M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.17M |
| Change in Payables | 1.19M | 1.67M | 849K | 11.45M | -14.67M | 63K | 1.9M | 2.22M | -4.75M | -279.19K |
| Cash from Investing | 0 | -31.59M | -8.66M | 40.1M | -11K | -54.59M | 13.96M | 23.34M | 18.21M | 1.09M |
| Capital Expenditures | 0 | -812K | -90K | -24K | -11K | -61K | -62K | -13K | -2K | -14.57K |
| CapEx % of Revenue | - | 159.84% | 10.36% | 64.86% | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 54.53K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -30.77K | -8.57K | 0 | 0 | -54.53K | 0 | 0 | 0 | 0 |
| Cash from Financing | 20.85M | 45.87M | 120.84M | 2.06M | 64.47M | 83.13M | -1.82M | 1.03M | 26.69M | 16.27M |
| Debt Issued (Net) | 0 | 0 | 14.51M | -1.03M | -5.49M | -6.52M | -2.25M | 0 | 0 | -109.46K |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 433K | 1000K | 1000K | 4M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 60K | 0 | 0 | 0 | 0 | 0 | -14.74M |
| Net Change in Cash | 9.55M▲ 0% | -16.32M▼ 270.9% | 36.19M▲ 321.7% | -39.78M▼ 209.9% | 9.93M▲ 124.9% | 12.69M▲ 27.9% | -6.38M▼ 150.3% | -15.02M▼ 135.3% | 18.05M▲ 220.2% | -2.4M▲ 0% |
| Free Cash Flow | -11.3M▲ 0% | -31.42M▼ 178.1% | -75.98M▼ 141.9% | -81.95M▼ 7.9% | -54.54M▲ 33.4% | -15.9M▲ 70.8% | -18.54M▼ 16.6% | -39.34M▼ 112.3% | -26.77M▲ 32.0% | -19.93M▲ 0% |
| FCF Margin % | - | -6184.25% | -8743.38% | -221475.68% | - | - | - | - | - | -5110.05% |
| FCF Growth % | - | -178.07% | -141.85% | -7.85% | 33.45% | 70.84% | -16.55% | -112.26% | 31.95% | 43.64% |
| FCF per Share | -0.81 | -57.21 | -120.30 | -78.04 | -2.27 | -1.46 | -1.51 | -3.04 | -1.36 | -1.36 |
| FCF Conversion (FCF/Net Income) | 0.84x | 1.04x | 0.98x | 0.79x | 1.05x | 0.17x | 0.42x | 1.02x | 1.08x | 0.74x |
| Interest Paid | 0 | 0 | 809K | 1.4M | 996K | 416K | 22K | 0 | 0 | 0 |
| Taxes Paid | 130K | 439K | 352K | 414K | 120K | 435K | 821K | 401K | 220K | 81K |
ITRM Key Ratios
Iterum Therapeutics plc (ITRM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -94.61% | -138.69% | -454.48% | - | -182.28% | -113.59% | -355.35% | - | 602.38% |
| Return on Invested Capital (ROIC) | -153.05% | -161.38% | -512.94% | - | -101.76% | -50.51% | -163.72% | -117.78% | -117.78% |
| Gross Margin | 100% | 100% | 100% | - | - | - | - | - | -171.28% |
| Net Margin | -5788.58% | -8867.2% | -278729.73% | - | - | - | - | - | -6913.08% |
| Debt / Equity | - | 0.18x | - | - | 0.61x | 1.08x | - | - | -4.57x |
| Interest Coverage | - | -179.72x | -118.49x | -2.13x | -4.42x | -12.87x | - | - | -10.61x |
| FCF Conversion | 1.04x | 0.98x | 0.79x | 1.05x | 0.17x | 0.42x | 1.02x | 1.08x | 0.74x |
| Revenue Growth | - | 71.06% | -95.74% | -100% | - | - | - | - | - |
ITRM Frequently Asked Questions
Iterum Therapeutics plc (ITRM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Iterum Therapeutics plc (ITRM) reported $0.4M in revenue for fiscal year 2024.
Iterum Therapeutics plc (ITRM) grew revenue by 0.0% over the past year. Growth has been modest.
Iterum Therapeutics plc (ITRM) reported a net loss of $27.0M for fiscal year 2024.
Dividend & Returns
Iterum Therapeutics plc (ITRM) had negative free cash flow of $19.9M in fiscal year 2024, likely due to heavy capital investments.
Explore More ITRM
Iterum Therapeutics plc (ITRM) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates